Lucid Diagnostics Inc’s Lock-Up Period To End on April 12th (NASDAQ:LUCD)

Lucid Diagnostics’ (NASDAQ:LUCDGet Rating) lock-up period will expire on Tuesday, April 12th. Lucid Diagnostics had issued 5,000,000 shares in its initial public offering on October 14th. The total size of the offering was $70,000,000 based on an initial share price of $14.00. After the end of Lucid Diagnostics’ lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Several research firms have commented on LUCD. Canaccord Genuity Group reduced their price objective on Lucid Diagnostics from $18.00 to $12.00 and set a “buy” rating on the stock in a report on Tuesday, March 29th. Canaccord Genuity Group dropped their target price on Lucid Diagnostics from $18.00 to $12.00 and set a “buy” rating on the stock in a research note on Tuesday, March 29th. BTIG Research lowered their price target on Lucid Diagnostics from $14.00 to $6.00 in a research report on Tuesday, April 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Lucid Diagnostics in a report on Friday, February 4th. Finally, Ascendiant Capital Markets initiated coverage on Lucid Diagnostics in a report on Monday, December 27th. They issued a “buy” rating and a $16.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $13.14.

Shares of LUCD stock opened at $2.80 on Tuesday. Lucid Diagnostics has a 1 year low of $2.72 and a 1 year high of $13.52. The business’s 50-day moving average price is $3.41.

Lucid Diagnostics (NASDAQ:LUCDGet Rating) last announced its quarterly earnings data on Monday, March 28th. The company reported ($0.32) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.12). As a group, sell-side analysts forecast that Lucid Diagnostics will post -1.2 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE purchased a new stake in shares of Lucid Diagnostics during the 4th quarter valued at $29,000. KCL Capital L.P. acquired a new stake in shares of Lucid Diagnostics in the 4th quarter valued at about $54,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Lucid Diagnostics during the 4th quarter valued at about $59,000. Virtu Financial LLC bought a new position in Lucid Diagnostics in the 4th quarter worth about $61,000. Finally, Susquehanna International Group LLP bought a new position in Lucid Diagnostics in the 4th quarter worth about $71,000.

About Lucid Diagnostics (Get Rating)

Lucid Diagnostics Inc is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc Lucid Diagnostics Inc is based in NEW YORK.

Read More

Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.